<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18400">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867358</url>
  </required_header>
  <id_info>
    <org_study_id>KT07-US-01</org_study_id>
    <nct_id>NCT02867358</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of KT07 Capsule in the U.S.A</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, and Placebo-controlled Phase II Clinical Study to Investigate the Safety and Efficacy of Two Doses of KT07 Compared to Placebo in Subjects With Acute Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yiling Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yiling Pharmaceutical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation
      of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains,
      fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of the duration of illness compared to placebo</measure>
    <time_frame>Up to 19 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects experience complications</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects experienced alleviation of influenza symptoms at every 24 hours</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of viral shedding</measure>
    <time_frame>At day 3 and day 6</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>High dose of KT07 capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of KT07 capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KT07 Capsule</intervention_name>
    <arm_group_label>High dose of KT07 capsule</arm_group_label>
    <arm_group_label>Low dose of KT07 capsule</arm_group_label>
    <other_name>Lianhua Qingwen Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Low dose of KT07 capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with mild or moderate acute uncomplicated influenza, and oral temperature of
             37.3-39.3℃ (99.1-102.8° F); plus at least one respiratory symptoms (nasal congestion,
             sore throat or cough); and at least one constitutional symptoms (aches and pains,
             fatigue, headache and chills or sweats).

          2. Subjects who have recently been exposed to patients infected with influenza virus
             with or without rapid influenza diagnostic test (RIDT) confirmed influenza infection
             (influenza virus A or B infection).

          3. Onset of symptoms less than 48 hours before Visit 1 (Screening; study drug
             administration visit) and receiving no antiviral/anti-influenza medication.

          4. Age 18 to 50 years old.

          5. Subjects who are able to understand and are willing to sign the informed consent form
             (ICF).

          6. All female subjects must have a negative urine pregnancy test result . All female
             subjects and male subjects and their spouse/partner must agree to use a medically
             acceptable method of contraception throughout the entire study period and for 30 days
             for female and 90 days for male subjects after study drug discontinuation.

        Exclusion Criteria:

          1. Subjects who suffer from severe influenza with oral temperature of more than 39.3℃
             (102.8°F) with or without other symptoms.

          2. Subjects who have any of following documented conditions: lower respiratory tract
             infection other than influenza, asthma requiring daily therapy, including acute flare
             of chronic asthma and bronchial asthma, chronic obstructive pulmonary disease (COPD),
             acute infectious disease, any other chronic respiratory disease, bacterial infection
             of respiratory system, such as: suppurative tonsillitis, acute tracheobronchitis,
             sinusitis, otitis; subjects with history of moderate to severe cardiac, hepatic,
             renal and hematopoietic disorders, bleeding tendency or hemorrhagic disease,mental
             and neurological system disease; subjects with hypertension, diabetes,
             hyperthyroidism and increased intraocular pressure; and subjects with cancer.

          3. Subjects with anatomical nasal obstruction or gross anatomical abnormalities. For
             example, nasal polyps or significant nasal septal deviation.

          4. Subjects who have to take other medications for the treatment of influenza or related
             symptoms, including but not limited to antipyretic and analgesic medicines,
             antibiotics, and antiviral drugs.

          5. Subjects with acute dyspnea, wheezing, moist rales on screening examination.

          6. Clinically very excessively obese subjects with BMI≥40.

          7. Alcoholism or substance abuse history.

          8. Subjects received influenza vaccine within 6 months.

          9. Participation in other clinical trial within 1 month.

         10. Pregnant or breast-feeding females subjects

         11. Allergy or known allergy to components of study medication.

         12. Allergy to aspirin or non-steroid anti-inflammatory drugs (NSAIDs), such as
             ibuprofen.

         13. Subjects received antipyretic and/or analgesic medications for conditions other than
             influenza such as back pain prior to randomization.

         14. Administration of immunomodulators, interferon inducers, homeopathic, hormonal other
             than hormone replacement therapy, antiviral and antibacterial drugs during last 4
             weeks before the first dose.

         15. Any other associated disease or condition which, in the opinion of the investigator,
             might restrict or impede participation in the study or affect the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuedong Gao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yiling Pharmaceutical Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anni Li, Pharm D</last_name>
    <phone>240-421-2794</phone>
    <email>lanni122508@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hope Clinical Research, Inc.</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hessam Aazami, MD</last_name>
      <phone>818-999-4673</phone>
      <email>haazami@hopeclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Health Care Group</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco L. Badar III, MD</last_name>
      <phone>562-924-8880</phone>
      <email>fbadarmdinc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lalla-Reddy Medical Corp.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujata Lalla-Reddy, MD</last_name>
      <phone>714-968-6789</phone>
      <email>DrReddy@suereddymd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Downtown L.A. Research Center, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salil U. Nadkarni, DO</last_name>
      <phone>213-261-3680</phone>
      <email>snadkarni@dtlaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMD Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imad A. El Asmar, MD</last_name>
      <phone>213-487-6889</phone>
      <email>imadelasmar@imdmedicalgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facey Medical Foundation</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riga Pemba, MD</last_name>
      <phone>818-869-7067</phone>
      <email>rpemba@facey.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yogesh K. Paliwal, MD</last_name>
      <phone>909-981-5321</phone>
      <email>apaliwal@empirereserach.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susann Varano, MD</last_name>
      <phone>203-386-3115</phone>
      <email>svarano@clinicalrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Center</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kartik Viswanathan, MD</last_name>
      <phone>860-886-1508</phone>
      <email>kartik.renuka@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sweet Hope Research Specialty, Inc</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Ebran-Gonzalez, MD</last_name>
      <phone>305-456-9062</phone>
      <email>r.gonzalez@sweethoperesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia Rodriguez Ables, MD</last_name>
      <phone>305-459-3578</phone>
      <email>LRAbles@finlaymedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panamerican Health Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis M. Ramos Gonez, MD</last_name>
      <phone>305-567-0060</phone>
      <email>lramosresearchmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AppleMed Reseach, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin J. Latorre, MD</last_name>
      <phone>305-667-8434</phone>
      <email>Dr.latorre@applemedresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M Haffizulla, MD</last_name>
      <phone>954-915-9991</phone>
      <email>jhaffizulla@sunrisemedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Nunez-Avila, MD</last_name>
      <phone>305-477-6750</phone>
      <email>Oavilaresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research</name>
      <address>
        <city>Williston</city>
        <state>Florida</state>
        <zip>32696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anubha Gupta, MD</last_name>
      <phone>352-490-4816</phone>
      <email>secr2gupta@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Efros, MD</last_name>
      <phone>516-746-2190</phone>
      <email>Efrosdoc@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Efros, MD</last_name>
      <phone>646-625-3011</phone>
      <email>researchdoc@nycclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex J. Slandzicki, MD</last_name>
      <phone>615-577-4017</phone>
      <email>drslandzicki@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Hoppers, MD</last_name>
      <phone>731-431-5027</phone>
      <email>drhoppers@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rowe, MD</last_name>
      <phone>615-415-3936</phone>
      <email>drrowe@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadie Dar, MD</last_name>
      <phone>615-693-9742</phone>
      <email>drdar@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Spring Hill</city>
        <state>Tennessee</state>
        <zip>37174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rennee N. Dhillon, MD</last_name>
      <phone>615-577-4017</phone>
      <email>drdhillon@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wade Family Medicine</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph D. Wade, DO</last_name>
      <phone>801-292-2850</phone>
      <email>rwade@progressiveclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc./ Foothill Family Clinic Draper</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen D. Coleman, MD</last_name>
      <phone>385-900-4077</phone>
      <email>scoleman@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Todd Peterson, MD</last_name>
      <phone>801-486-3021</phone>
      <phone_ext>3370</phone_ext>
      <email>jpeterson@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Christensen, MD</last_name>
      <phone>801-365-1032</phone>
      <phone_ext>3506</phone_ext>
      <email>schristensen@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc./ FirstMed East</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Plunkett, MD</last_name>
      <phone>801-733-4057</phone>
      <email>splunkett@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CopperView Medical Center</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary D. Tipton, MD</last_name>
      <phone>801-294-9911</phone>
      <email>tipton@rx-research.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 16, 2016</lastchanged_date>
  <firstreceived_date>August 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute uncomplicated influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
